Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 

Investor Overview

Analyst Coverage

Firm Analyst
Canaccord Genuity
John Newman Ph.D.
Citi
Mohit Bansal
Cowen
Chris Shibutani M.D.
Goldman Sachs
Terence Flynn Ph.D.
Guggenheim Partners
Michael Schmidt Ph.D.
JP Morgan
Anupam Rama
Needham & Company
Chad Messer Ph.D.
Oppenheimer & Co.
Leah Rush Cann
Piper Jaffray & Co
Tyler Van Buren
RBC Capital Markets
Kennen MacKay Ph.D.

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.